Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OrganiGramProvention BioChinook TherapeuticsAkouosOdonate Therapeutics
SymbolNASDAQ:OGINASDAQ:PRVBNASDAQ:KDNYNASDAQ:AKUSNASDAQ:ODT
Price Information
Current Price$2.34$7.85$14.78$14.53$3.26
52 Week RangeHoldBuyBuyBuyHold
MarketRank™
Overall Score1.61.61.41.61.8
Analysis Score4.24.43.53.43.0
Community Score3.02.72.92.52.1
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.01.72.5
Earnings & Valuation Score0.60.00.60.61.3
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyHold
Consensus Price Target$4.41$19.75$30.33$31.67$19.33
% Upside from Price Target88.51% upside151.59% upside105.23% upside117.94% upside493.05% upside
Trade Information
Market Cap$603.91 million$510.17 million$650.06 million$490.23 million$125.46 million
Beta0.33.340.26N/A0.66
Average Volume23,663,7071,368,585119,731213,4033,696,222
Sales & Book Value
Annual Revenue$64.61 millionN/A$17.26 millionN/AN/A
Price / Sales8.41N/A36.29N/AN/A
Cashflow$0.02 per shareN/AN/AN/AN/A
Price / Cash101.50N/AN/AN/AN/A
Book Value$1.04 per share$1.72 per share$4.07 per shareN/A$5.06 per share
Price / Book2.25N/A3.63N/AN/A
Profitability
Net Income$-101,290,000.00$-43,280,000.00$-82,370,000.00N/A$-111,820,000.00
EPS($0.08)($1.06)($5.15)N/A($4.05)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-207.26%N/A-215.80%N/AN/A
Return on Equity (ROE)-10.00%-67.66%-112.72%N/A-85.75%
Return on Assets (ROA)-7.14%-62.27%-21.36%N/A-71.45%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.17%N/AN/AN/AN/A
Current Ratio2.66%9.23%11.27%37.39%6.68%
Quick Ratio3.39%9.23%11.27%37.39%6.68%
Ownership Information
Institutional Ownership Percentage10.84%39.42%N/A88.70%96.00%
Insider Ownership PercentageN/A14.40%5.90%N/A48.90%
Miscellaneous
Employees516594354134
Shares Outstanding232.27 million63.38 million42.38 million34.40 million38.60 million
Next Earnings Date7/20/2021 (Estimated)5/6/2021 (Estimated)5/3/2021 (Estimated)7/5/2021 (Estimated)4/27/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Odonate Therapeutics, Inc. (NASDAQ:ODT) Receives Average Rating of "Hold" from AnalystsOdonate Therapeutics, Inc. (NASDAQ:ODT) Receives Average Rating of "Hold" from Analysts
americanbankingnews.com - April 17 at 10:53 AM
Odonate Therapeutics, Inc. (NASDAQ:ODT) Sees Significant Decrease in Short InterestOdonate Therapeutics, Inc. (NASDAQ:ODT) Sees Significant Decrease in Short Interest
americanbankingnews.com - April 14 at 11:56 AM
Odonate Therapeutics (ODT) is Oversold: Can It Recover?Odonate Therapeutics (ODT) is Oversold: Can It Recover?
finance.yahoo.com - April 9 at 9:59 AM
Odonate Therapeutics Target of Unusually Large Options Trading (NASDAQ:ODT)Odonate Therapeutics Target of Unusually Large Options Trading (NASDAQ:ODT)
americanbankingnews.com - April 7 at 2:18 PM
Odonate Therapeutics, Inc. (NASDAQ:ODT) Expected to Announce Earnings of -$0.85 Per ShareOdonate Therapeutics, Inc. (NASDAQ:ODT) Expected to Announce Earnings of -$0.85 Per Share
americanbankingnews.com - April 6 at 8:12 PM
Odonate Therapeutics, Inc. (NASDAQ:ODT) Stock Forecast for 2021: Bullish Signs Point to $4 per ShareOdonate Therapeutics, Inc. (NASDAQ:ODT) Stock Forecast for 2021: Bullish Signs Point to $4 per Share
marketingsentinel.com - March 29 at 9:31 AM
Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Dont?Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Don't?
finance.yahoo.com - March 24 at 10:19 AM
Odonate Therapeutics stock plummets toward record low after plan to wind down operationsOdonate Therapeutics stock plummets toward record low after plan to 'wind down' operations
finance.yahoo.com - March 22 at 6:11 PM
Why Odonate, Marker Therapeutics and Dyadic Are Moving MondayWhy Odonate, Marker Therapeutics and Dyadic Are Moving Monday
msn.com - March 22 at 1:10 PM
Odonate Therapeutics To Wind Down Operations - Quick FactsOdonate Therapeutics To Wind Down Operations - Quick Facts
nasdaq.com - March 22 at 1:10 PM
Why Odonate Therapeutics Stock Is Crashing TodayWhy Odonate Therapeutics Stock Is Crashing Today
finance.yahoo.com - March 22 at 1:10 PM
Odonate Therapeutics Announces Discontinuation of Development of TesetaxelOdonate Therapeutics Announces Discontinuation of Development of Tesetaxel
finance.yahoo.com - March 22 at 8:10 AM
What Will Odonate Therapeutics, Inc. (NASDAQ:ODT) Be Like After It Drops -74.42% From Its Highs?What Will Odonate Therapeutics, Inc. (NASDAQ:ODT) Be Like After It Drops -74.42% From Its Highs?
marketingsentinel.com - February 7 at 6:39 PM
Revisiting Odonate TherapeuticsRevisiting Odonate Therapeutics
seekingalpha.com - February 2 at 8:09 PM
Trade Alert: The Independent Director Of Odonate Therapeutics, Inc. (NASDAQ:ODT), Craig Johnson, Has Just Spent US$51k Buying A Few More SharesTrade Alert: The Independent Director Of Odonate Therapeutics, Inc. (NASDAQ:ODT), Craig Johnson, Has Just Spent US$51k Buying A Few More Shares
nasdaq.com - January 2 at 12:40 PM
3 Beaten-Down Stocks Insiders Scooped Up as 2020 Ended3 Beaten-Down Stocks Insiders Scooped Up as 2020 Ended
finance.yahoo.com - January 2 at 7:40 AM
Thinking about buying stock in Gevo Inc, Inovio Pharmaceuticals, Odonate Therapeutics, Cocrystal Pharma, or Vuzix Corp?Thinking about buying stock in Gevo Inc, Inovio Pharmaceuticals, Odonate Therapeutics, Cocrystal Pharma, or Vuzix Corp?
marketwatch.com - December 24 at 12:26 PM
Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
finance.yahoo.com - December 11 at 12:28 PM
Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020
finance.yahoo.com - December 1 at 9:07 AM
ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: November 16, 2020ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: November 16, 2020
finance.yahoo.com - November 16 at 6:56 PM
ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline ...ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline ...
businesswire.com - November 16 at 1:56 PM
FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmFINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - November 16 at 1:56 PM
FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmFINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - November 16 at 1:56 PM
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmDEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - November 15 at 1:50 PM
FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action – ODTFINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action – ODT
feeds.benzinga.com - November 15 at 1:07 PM
DateCompanyBrokerageAction
4/20/2021OrganiGramCIBCReiterated Rating
4/15/2021OrganiGramStifel NicolausBoost Price Target
4/14/2021OrganiGramRaymond JamesLower Price Target
4/14/2021OrganiGramCanaccord GenuityBoost Price Target
4/13/2021OrganiGramAlliance Global PartnersLower Price Target
4/8/2021OrganiGramBMO Capital MarketsUpgrade
3/11/2021OrganiGramCantor FitzgeraldReiterated Rating
8/10/2020OrganiGramJefferies Financial GroupReiterated Rating
4/19/2021Provention BioHC WainwrightReiterated Rating
4/19/2021Provention BioChardan CapitalLower Price Target
4/15/2021Provention BioSVB LeerinkLower Price Target
4/15/2021Provention BioRoyal Bank of CanadaReiterated Rating
4/9/2021Provention BioOppenheimerReiterated Rating
3/22/2021Chinook TherapeuticsBloom BurtonReiterated Rating
1/6/2021Chinook TherapeuticsWedbushInitiated Coverage
11/2/2020Chinook TherapeuticsEvercore ISIInitiated Coverage
10/6/2020Chinook TherapeuticsWilliam BlairReiterated Rating
3/30/2021AkouosBank of AmericaDowngrade
7/21/2020AkouosBTIG ResearchInitiated Coverage
7/21/2020AkouosPiper SandlerInitiated Coverage
7/21/2020AkouosCowenInitiated Coverage
3/22/2021Odonate TherapeuticsLifesci CapitalDowngrade
3/22/2021Odonate TherapeuticsThe Goldman Sachs GroupLower Price Target
9/9/2020Odonate TherapeuticsCi CapitalReiterated Rating
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.